Truxima (rituximab) vs Epkinly (epcoritamab-bysp)
Truxima (rituximab) vs Epkinly (epcoritamab-bysp)
Truxima (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of patients with certain types of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. It is a biosimilar to the original rituximab product, Rituxan, and works by targeting CD20-positive B cells, which are implicated in these conditions. Epkinly (epcoritamab-bysp), on the other hand, is a bispecific antibody that targets both CD20 on B cells and CD3 on T cells, designed to engage the body's immune system to attack B cells, and is being investigated for the treatment of B-cell non-Hodgkin lymphoma. Unlike Truxima, Epkinly's bispecific nature allows it to bring T cells into close proximity with B cells, potentially enhancing the immune response against cancerous B cells. Patients should consult with their healthcare provider to determine which medication is more appropriate for their condition, taking into account the specific indication, mechanism of action, safety profile, and the current stage of clinical approval.
Difference between Truxima and Epkinly
| Metric | Truxima (rituximab) | Epkinly (epcoritamab-bysp) |
|---|---|---|
| Generic name | Rituximab | Epcoritamab-bysp |
| Indications | Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis | Currently being investigated for the treatment of B-cell non-Hodgkin lymphoma |
| Mechanism of action | CD20-directed cytolytic antibody | Bispecific antibody targeting CD3 on T-cells and CD20 on B-cells |
| Brand names | Truxima, Rituxan, MabThera | Epkinly |
| Administrative route | Intravenous infusion | Subcutaneous injection |
| Side effects | Infusion reactions, infections, body aches, fatigue, skin rashes | Currently under investigation, but may include cytokine release syndrome, injection site reactions, and neutropenia |
| Contraindications | Hypersensitivity to rituximab or any component of the formulation, active severe infections | Not fully established yet, but likely similar to other immunomodulatory antibodies |
| Drug class | Monoclonal antibody | Bispecific monoclonal antibody |
| Manufacturer | Celltrion, Genentech | Genmab, AbbVie |
Efficacy
Truxima (Rituximab) Efficacy in Lymphoma
Truxima, a biosimilar to the original rituximab, is an anti-CD20 monoclonal antibody that targets CD20-positive B cells. It is used in the treatment of various types of non-Hodgkin lymphoma (NHL), including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL), as well as chronic lymphocytic leukemia (CLL). Clinical trials have shown that Truxima, in combination with chemotherapy, improves overall survival and progression-free survival in patients with these types of lymphoma. The efficacy of Truxima in the treatment of lymphoma is comparable to that of the reference product, rituximab, which has been a cornerstone in lymphoma therapy for years.
In follicular lymphoma, Truxima has been shown to induce remission and prolong survival when used as a first-line treatment in combination with chemotherapy and as a maintenance therapy. For patients with DLBCL, Truxima has significantly improved treatment outcomes when used in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone). This combination, known as R-CHOP, is considered a standard treatment regimen for DLBCL.
Epkinly (Epcoritamab-bysp) Efficacy in Lymphoma
Epkinly (epcoritamab-bysp) is an investigational bispecific antibody designed to target both CD20 on B cells and CD3 on T cells, thereby engaging the body's immune system to fight against lymphoma cells. While it is not yet approved, early clinical trials have shown promise in the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, including DLBCL and follicular lymphoma. The dual targeting mechanism of action is intended to enhance the immune system's ability to detect and destroy malignant B cells.
In early phase clinical trials, Epkinly has demonstrated an ability to induce complete and partial responses in a significant proportion of patients with relapsed or refractory B-cell non-Hodgkin lymphoma. These trials are ongoing, and the data collected will further elucidate the efficacy and safety profile of Epkinly. The potential for Epkinly to become a new therapeutic option for lymphoma patients is under investigation, and the results of these trials are eagerly anticipated by the medical community.
Regulatory Agency Approvals
Truxima
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Epkinly
-
Food and Drug Administration (FDA), USA
Access Truxima or Epkinly today
If Truxima or Epkinly are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us